Bright Minds Biosciences Inc (DRUG) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bright Minds Biosciences Inc   (NASDAQ: DRUG)

Bright Minds Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Bright Minds Biosciences Inc in the fourth quarter 2025?
Bright Minds Biosciences Inc recorded a cumulative net loss of $-9 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -14.91%.

Within the Major Pharmaceutical Preparations industry 70 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 3111.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Sep 30 2024)
IV. Quarter
Y / Y Equity Change 1381.93 % 1381.93 % 1381.93 % 1381.93 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -9 -2 -2 -2 -2
Return On Equity (TTM) -14.91 % -4.45 % -6.4 % -11.36 % -50.61 %
DRUG's Total Ranking # 3111 # 0 # # #
Equity (TTM) in Millions 63 63 63 63 4
Seq. Equity Change 0 % 0 % 0 % 1381.93 % 0 %
Seq. Net Income Change - - - - -

Back to DRUG Management Effectiveness >> DRUG's 5 Years Annual ROE >> Compare DRUG ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 71
Sector # 232
Overall # 3111

Return On Equity Statistics
High Average Low
-14.91 %
-79.8 %
-141.95 %
(Sep 30 2025)   (Sep 30 2022)





DRUG Annual Return On Equity (Sep 30 2025)
2025		 (Sep 30 2024)
2024		 (Sep 30 2023)
2023		 (Sep 30 2022)
2022		 (Sep 30 2020)
2021
Total Equity in Millions 63 4 5 8 1
Y / Y Equity Change 1381.93 % -16.09 % -37.41 % 1375.27 % -
Net Income in Millions -9 -2 -6 -11 0
Y / Y Net Income Change - - - - -
Return On Equity -14.91 % -50.61 % -111.73 % -141.95 % -65.25 %

Back to DRUG Management Effectiveness >> DRUG's 5 Years Annual ROE >> Compare DRUG ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
DRUG's' Return on Equity at Yahoo Finance
DRUG's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DRUG's Competitors
Subscribers only: Roe for Bright Minds Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for DRUG's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-07-07T10:24:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.